Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.
Fraticelli P, Gabrielli B, Pomponio G, Valentini G, Bosello S, Riboldi P, Gerosa M, Faggioli P, Giacomelli R, Del Papa N, Gerli R, Lunardi C, Bombardieri S, Malorni W, Corvetta A, Moroncini G, Gabrielli A; Imatinib in Scleroderma Italian Study Group.
Fraticelli P, et al. Among authors: pomponio g.
Arthritis Res Ther. 2014 Jul 8;16(4):R144. doi: 10.1186/ar4606.
Arthritis Res Ther. 2014.
PMID: 25007944
Free PMC article.
Clinical Trial.